^（131）Ⅰ－碘化油内照射治疗肝癌的初步观察

Preliminary observation of￣(131)I-lipiodol internal radiation therapy for liver cancer

报道了１３１Ⅰ－碘化油经肝动脉注射（Ａ法）或Ｂ超导向经皮穿刺注射（Ｂ法）治疗２０例肝癌的初步观察．放射性核素显像证实１３１Ⅰ－碘化油主要浓集于肿瘤内。Ａ法及Ｂ法的癌肝比值分别为３．８７±２．７７及９．１５±３．４１；１３１Ⅰ－碘化油在癌内的有效半减期分别为４．７±１．９２ｄ及６．２２±０．６１ｄ，肺内放射性（肺／肺＋肝）为１３．１９±３．０１％及５．１９±２．２８％，说明Ｂ法的生物学分布优于Ａ法。临床结果ＡＦＰ下降占６４．３％，肿瘤缩小占６６．７％，除有短暂发热及胆红质、ＳＧＰＴ增高外，未见其它毒副反应．

Internal radiation therapy of 131 I- lipiodol with hepatic artery injection(Method A) and B-ultrasound guided percutaneous puncture(Method B) was observed in twenty patients with liver cancer. The radionuclide images showed that the 131I-lipiodol acumulated in tumor mainly. The radioactivity of tumor/liver (T/L)ratio in method A and method B was 3.87 ± 2.77 and 9.15 ± 3.41, the effective half-life of 131I- lipiodol in tumor was 4.7 ± 1.92 days and 6.22 ± 0.61 days, and the radioactivity of lung was 13.19 ± 3.01% and 5.19 ± 2.28% respectively. These results suggested that the 131 I- lipiodol biodistribution in method B is better than method A. Clinical results showed that AFP levels dropped rapidly in 64.3% of the patients with positive AFP.A shrinkage in tumor size was observed in 66.7% of patients. With the transient fever, elevated bilirubin and SGPT in some patients, no other toxicity and adverse reactions were observed.